Latest News

Araris Biotech closes $24m Series A financing round

Araris’ linker technology enables site-specific payload attachment to a specific amino acid (Q295) within the IgG-Fc framework. When a payload is attached to this site, the antibody still maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong peptide bond resulting in exceptional stability in the blood stream and thus minimal adverse effects. © Araris Biotech AG


by tg

Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.

The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular Lymphoma Innovation and from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine. Proceeds from the financing will be used to support the further development and advancement of Araris’ preclincial antibody-drug conjugate (ADC) candidates, created using the company’s proprietary linker technology.

Araris Biotech AG’s inker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs. Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

Spain set to unveil the potential of the biologisation of medicine and food production

At BioSpain 2023, several panels discussed the Spanish EU Presidency's goal of setting the course for the internationally competitive use of...

Antiverse and GlobalBio Inc. extend collaboration

AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

Recordbreaking BIO-Europe in Munich, but: back to 2019

Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...

Austrian Kern Tec raises €12m in Series A financing

Food tech specialist Kern Tec GmbH (Vienna) will use €12m from a €12m Series financing to scale up manufacturing of dairy products from upcycled...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics

Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Synerkine Pharma BV secures EUR 12.1m in Series A extension

The Series A extension was led by Flerie with participation of existing investor Thuja Capital and new investors InnovationQuarter Capital and...

Abingworth raises $356m for new CCD fund

London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...